Immunotherapy for recurrent malignant melanoma: Efficacy of BCG in prolonging the postoperative disease free interval and survival

J. U. Gutterman, Stephen P Richman, C. M. McBride

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In this report, the authors summarize updated results with adjuvant immunotherapy with bacillus Calmette-Guerin (BCG) for patients with recurrent malignant melanoma. This program was initiated in 1971.

Original languageEnglish
Title of host publicationRecent Results in Cancer Research
Pages359-362
Number of pages4
VolumeVol. 68
StatePublished - Dec 1 1979
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Immunotherapy for recurrent malignant melanoma: Efficacy of BCG in prolonging the postoperative disease free interval and survival'. Together they form a unique fingerprint.

Cite this